Cite
HARVARD Citation
Hanauer, S. et al. (n.d.). P052 Biosimilar BI 695501 Demonstrates Non-Inferior Efficacy and Comparable Safety to Adalimumab Reference Product in Patients With Active Crohn's Disease. American journal of gastroenterology. p. . [Online].